- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Akebia Therapeutics (NASDAQ:AKBA), Quotes and News Summary
Akebia Therapeutics (NASDAQ: AKBA)
Earnings
see more| Q3 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-11-03 | ||||||
| REV | |||||||
| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.310 | 0.230 | 0.5400 | ||||
| REV | 49.730M | 126.759M | 77.029M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Akebia Therapeutics Questions & Answers
You can purchase shares of Akebia Therapeutics (NASDAQ: AKBA) through any online brokerage.
Other companies in Akebia Therapeutics’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Connect Biopharma Hldgs (NASDAQ:CNTB), Lumos Pharma (NASDAQ:LUMO), Evaxion Biotech (NASDAQ:EVAX) and Bolt Biotherapeutics (NASDAQ:BOLT).
The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by HC Wainwright & Co. on Monday, May 16, 2022. The analyst firm set a price target for 1.25 expecting AKBA to rise to within 12 months (a possible 207.88% upside). 6 analyst firms have reported ratings in the last year.
The stock price for Akebia Therapeutics (NASDAQ: AKBA) is $0.406 last updated August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Akebia Therapeutics.
Akebia Therapeutics’s Q3 earnings are confirmed for Thursday, November 3, 2022.
There is no upcoming split for Akebia Therapeutics.
Akebia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.